Evaxion flags new press release available on EVX-01 three-year phase 2 melanoma data presentation at ESMO 2026
EVAX•EVX-01 three-year phase 2 melanoma data presentation
Evaxion posted a release on EVX-01, outlining plans to present three-year phase 2 efficacy data in advanced melanoma at ESMO 2026.
- Presentation is scheduled for Oct. 24, 2026 in Madrid.
- The data include a third-year extension with EVX-01 monotherapy in a subset of patients.
- Prior two-year readout showed 75% ORR in 16 patients, with 92% still responding at two years and no relapses reported.
